Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Common Equity (2016 - 2025)

Historic Common Equity for Lipocine (LPCN) over the last 13 years, with Q3 2025 value amounting to $14.1 million.

  • Lipocine's Common Equity fell 2602.41% to $14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.1 million, marking a year-over-year decrease of 2602.41%. This contributed to the annual value of $21.0 million for FY2024, which is 308.36% up from last year.
  • As of Q3 2025, Lipocine's Common Equity stood at $14.1 million, which was down 2602.41% from $17.1 million recorded in Q2 2025.
  • Lipocine's 5-year Common Equity high stood at $45.6 million for Q4 2021, and its period low was $14.1 million during Q3 2025.
  • In the last 5 years, Lipocine's Common Equity had a median value of $28.6 million in 2023 and averaged $29.0 million.
  • In the last 5 years, Lipocine's Common Equity skyrocketed by 54691.83% in 2021 and then plummeted by 4283.86% in 2023.
  • Lipocine's Common Equity (Quarter) stood at $45.6 million in 2021, then decreased by 21.8% to $35.6 million in 2022, then tumbled by 42.84% to $20.4 million in 2023, then rose by 3.08% to $21.0 million in 2024, then crashed by 32.65% to $14.1 million in 2025.
  • Its Common Equity was $14.1 million in Q3 2025, compared to $17.1 million in Q2 2025 and $19.2 million in Q1 2025.